scholarly journals Higher Dispositional Optimism Predicts Better Health-Related Quality of Life After Esophageal Cancer Surgery: A Nationwide Population-Based Longitudinal Study

2021 ◽  
Author(s):  
Yangjun Liu ◽  
Erik Pettersson ◽  
Anna Schandl ◽  
Sheraz Markar ◽  
Asif Johar ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Dispositional Optimism ◽  
Cancer Surgery ◽  
Life Questionnaire ◽  
Post Surgery ◽  
Esophageal Cancer Surgery ◽  
Global Quality ◽  
Global Quality Of Life

Abstract Purpose To assess whether higher dispositional optimism could predict better health-related quality of life (HRQL) after esophageal cancer surgery. Methods This Swedish nationwide longitudinal study included 192 patients who underwent esophagectomy for cancer. The exposure was dispositional optimism measured by the Life Orientation Test-Revised (LOT-R) at 1 year post-surgery. Patients were categorized into four subgroups (very low, moderately low, moderately high, and very high dispositional optimism) based on the quartile of the LOT-R sum score. The outcome was HRQL assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) and Quality of Life Questionnaire-Esophago-Gastric module 25 (QLQ-OG25) at 1, 1.5, and 2 years post-surgery. Linear mixed-effects models, adjusted for potential confounders, were used to examine the mean score difference (MSD) with 95% confidence interval of HRQL among the four patient subgroups. Results Patients with very high dispositional optimism reported clinically relevantly better global quality of life, emotional function, and social function (MSD range 10–16) and less severe symptoms in pain, dyspnea, diarrhea, eating difficulty, anxiety, dry mouth, trouble with taste, worry about weight loss, and self-doubt about body image (MSD range − 9 to − 22) than patients with lower dispositional optimism. Patients with moderately high dispositional optimism reported clinically and statistically significantly better global quality of life (MSD 10) and less severe diarrhea (MSD − 9) than patients with lower dispositional optimism. Adjusted MSDs were constant over the three time points in all aspects except for eating difficulty. Conclusions Measuring dispositional optimism could help identify patients at higher risk of poor HRQL recovery after esophageal cancer surgery.

scholarly journals The Influence of Comorbidity on Health-Related Quality of Life After Esophageal Cancer Surgery

2020 ◽  
Vol 27 (8) ◽  
pp. 2637-2645
Author(s):  
Lovisa Backemar ◽  
Asif Johar ◽  
Anna Wikman ◽  
Janine Zylstra ◽  
James Gossage ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Cancer Surgery ◽  
Health Related Quality ◽  
Esophageal Cancer Surgery ◽  
Related Quality ◽  
Health Related

Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer

1999 ◽  
Vol 17 (10) ◽  
pp. 3270-3275 ◽  
Author(s):  
David H. Ilson ◽  
Leonard Saltz ◽  
Peter Enzinger ◽  
Ying Huang ◽  
Alice Kornblith ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Squamous Carcinoma ◽  
Similar Response ◽  
Life Questionnaire ◽  
Significant Activity ◽  
Actuarial Survival ◽  
European Organization ◽  
Global Quality Of Life

PURPOSE: To evaluate the response, toxicity, survival, and quality of life in patients with unresectable or metastatic esophageal cancer treated with weekly irinotecan and cisplatin. PATIENTS AND METHODS: Thirty-five patients with metastatic or unresectable esophageal adenocarcinoma (23 patients) or squamous cell carcinoma (12 patients) were treated. No prior chemotherapy was allowed. The majority of patients had metastatic and bidimensionally measurable disease (34 patients each [97%]). Patients were treated with cisplatin 30 mg/m2 and irinotecan 65 mg/m2, repeated weekly for 4 weeks, followed by a 2-week rest period. Treatment was recycled every 6 weeks. Degree of dysphagia relief was monitored, and quality of life was measured prospectively using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 and Functional Assessment of Cancer Therapy–General instruments. RESULTS: Thirty-five patients were assessable for response and toxicity. Major objective responses were observed in 20 patients (57%; 95% confidence interval, 41% to 73%), including two complete responses (6%). Similar response rates were observed for adenocarcinoma (12 of 23 patients; 52%) and squamous carcinoma (eight of 12 patients; 66%). The median duration of response was 4.2 months (range, 1 to 8.8+ months). Median actuarial survival was 14.6 months (range, 1 to 15.2+ months). In 20 patients with dysphagia assessable at baseline, 18 (90%) noted either improvement or resolution of dysphagia on chemotherapy. Global quality of life improved in responding patients, primarily because of improvements in pain, emotional state, and relationships with family and friends. Toxicity was relatively mild and included only three patients (9%) with grade 4 neutropenia and four (11%) with grade 3 diarrhea. There were no treatment-related deaths. CONCLUSION: The combination of weekly cisplatin plus irinotecan had significant activity in metastatic esophageal carcinoma and resulted in significant relief of dysphagia. The regimen was well tolerated, with acceptable myelosuppression and rare treatment-related diarrhea. Further evaluation of the combination of weekly irinotecan and cisplatin, including the addition of other agents to this regimen, is indicated.

Dispositional optimism and terminal decline in global quality of life.

2015 ◽  
Vol 51 (6) ◽  
pp. 856-863 ◽  
Author(s):  
Oleg Zaslavsky ◽  
Yuval Palgi ◽  
Eileen Rillamas-Sun ◽  
Andrea Z. LaCroix ◽  
Eliezer Schnall ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Dispositional Optimism ◽  
Global Quality ◽  
Global Quality Of Life

Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone

1999 ◽  
Vol 17 (6) ◽  
pp. 1654-1654 ◽  
Author(s):  
David Osoba ◽  
Ian F. Tannock ◽  
D. Scott Ernst ◽  
Alan J. Neville
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Global Quality ◽  
Global Quality Of Life ◽  
Related Quality ◽  
Health Related

PURPOSE: A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer. The purpose of this study was to assess the effects of these treatments on health-related quality of life (HQL). PATIENTS AND METHODS: Men with metastatic prostate cancer (n = 161) were randomized to receive either daily prednisone alone or mitoxantrone (every 3 weeks) plus prednisone. Those who received prednisone alone could have mitoxantrone added after 6 weeks if there was no improvement in pain. HQL was assessed before treatment initiation and then every 3 weeks using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ-C30) and the Quality of Life Module–Prostate 14 (QOLM-P14), a trial-specific module developed for this study. An intent-to-treat analysis was used to determine the mean duration of HQL improvement and differences in improvement duration between groups of patients. RESULTS: At 6 weeks, both groups showed improvement in several HQL domains, and only physicalfunctioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group. After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P = .009), four functioning domains, and nine symptoms (.001 < P < .01), and the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P < .05). The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P < .003). CONCLUSION: Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.

Determinants of global quality of life before and after major cancer surgery: an exploratory study

2009 ◽  
Vol 18 (9) ◽  
pp. 1131-1136 ◽  
Author(s):  
Martin Rutegård ◽  
Rachael Hughes ◽  
Pernilla Lagergren ◽  
Jane M. Blazeby
Keyword(s):  
Quality Of Life ◽  
Exploratory Study ◽  
Cancer Surgery ◽  
Global Quality ◽  
Global Quality Of Life ◽  
Before And After

Influence of Major Postoperative Complications on Health-Related Quality of Life Among Long-Term Survivors of Esophageal Cancer Surgery

2012 ◽  
Vol 30 (14) ◽  
pp. 1615-1619 ◽  
Author(s):  
Maryam Derogar ◽  
Nicola Orsini ◽  
Omid Sadr-Azodi ◽  
Pernilla Lagergren
Keyword(s):  
Quality Of Life ◽  
Esophageal Cancer ◽  
Postoperative Complications ◽  
Cancer Surgery ◽  
Health Related Quality ◽  
Esophageal Cancer Surgery ◽  
Related Quality ◽  
Health Related

Purpose To evaluate the effect of major postoperative complications on health-related quality of life (HRQL) in 5-year survivors of esophageal cancer surgery. Patients and Methods This study was based on the Swedish Esophageal and Cardia Cancer register with almost complete nationwide coverage and data on esophageal cancer surgery collected prospectively between 2001 and 2005. Patients who were alive 5 years after surgery were eligible. HRQL was assessed longitudinally until 5 years after surgery by using the validated European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and OES18. Linear mixed models were used to assess the mean score difference (MD) with 95% CIs of each aspect of HRQL in patients with or without major postoperative complications. Adjustment was made for several potential confounders. Results Of 153 patients who survived 5 years, 141 patients (92%) answered the 5-year HRQL questionnaires. Of these individuals, 46 patients (33%) sustained a major postoperative complication. Dyspnea (MD, 15; 95% CI, 6 to 23), fatigue (MD, 13; 95% CI, 5 to 20), and eating restrictions (MD, 10; 95% CI, 2 to 17) were clinically and statistically significantly deteriorated throughout the follow-up in patients with major postoperative complications compared with patients without major complications. Although problems with choking declined to levels comparable with patients without major postoperative complications, sleep difficulties and gastroesophageal reflux progressively worsened during follow-up. Conclusion The occurrence of postoperative complications exerts a long-lasting negative effect on HRQL in patients who survive 5 years after esophagectomy for cancer.

Sign in / Sign up

Export Citation Format

Share Document